CALITHERA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 USD | 0.00% |
|
-20.32% | -33.33% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 296.2 | 152.9 | 307.1 | 346.4 | 49.84 | 15.86 |
| Enterprise Value (EV) 1 | 132.4 | 16.73 | 157.9 | 238 | -6.656 | -7.924 |
| P/E ratio | -9.89 x | -2.69 x | -3.01 x | -3.75 x | -0.43 x | -0.41 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 11.4 x | 6.87 x | - | - | 5.11 x | - |
| EV / Revenue | 5.1 x | 0.75 x | - | - | -0.68 x | - |
| EV / EBITDA | -4.52 x | -0.29 x | -1.71 x | -2.61 x | 0.06 x | 0.19 x |
| EV / FCF | 7.12 x | -0.32 x | -3.42 x | -4.62 x | 0.11 x | 0.28 x |
| FCF Yield | 14% | -313% | -29.3% | -21.6% | 950% | 356% |
| Price to Book | 1.99 x | 1.23 x | 2.55 x | 3.39 x | 6.12 x | -8.14 x |
| Nbr of stocks (in thousands) | 1,774 | 1,906 | 2,689 | 3,528 | 3,746 | 4,865 |
| Reference price 2 | 167.0 | 80.20 | 114.2 | 98.20 | 13.30 | 3.260 |
| Announcement Date | 3/8/18 | 3/7/19 | 3/11/20 | 3/16/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 25.96 | 22.25 | - | - | 9.75 | - |
| EBITDA 1 | -29.32 | -56.78 | -92.42 | -91.02 | -114 | -41.82 |
| EBIT 1 | -29.69 | -57.28 | -92.9 | -91.39 | -114.2 | -42.07 |
| Operating Margin | -114.37% | -257.4% | - | - | -1,171.62% | - |
| Earnings before Tax (EBT) 1 | -27.83 | -54.63 | -89.86 | -90.14 | -115.1 | -39.65 |
| Net income 1 | -27.83 | -54.63 | -89.86 | -90.14 | -115.1 | -39.65 |
| Net margin | -107.21% | -245.48% | - | - | -1,180.39% | - |
| EPS 2 | -16.89 | -29.85 | -37.99 | -26.20 | -31.16 | -7.943 |
| Free Cash Flow 1 | 18.6 | -52.44 | -46.19 | -51.52 | -63.24 | -28.17 |
| FCF margin | 71.66% | -235.66% | - | - | -648.6% | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/8/18 | 3/7/19 | 3/11/20 | 3/16/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 3 | 6.75 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.9 | -22.66 | -20.77 | -14.31 | -11.15 | -69.21 | -13.83 | -11.38 | -9.526 |
| Operating Margin | - | - | - | -476.9% | -165.19% | - | - | - | - |
| Earnings before Tax (EBT) 1 | -22.73 | -22.57 | -20.4 | -14.31 | -11.17 | -69.21 | -13.84 | -9.077 | -9.802 |
| Net income 1 | -22.73 | -22.57 | -20.4 | -14.31 | -11.17 | -69.21 | -13.84 | -9.077 | -9.802 |
| Net margin | - | - | - | -477.03% | -165.51% | - | - | - | - |
| EPS 2 | -6.400 | -6.400 | -5.600 | -3.800 | -3.000 | -18.40 | -3.600 | -1.590 | -2.010 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/5/20 | 3/16/21 | 5/6/21 | 8/5/21 | 11/9/21 | 3/31/22 | 5/10/22 | 8/15/22 | 11/14/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 164 | 136 | 149 | 108 | 56.5 | 23.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 18.6 | -52.4 | -46.2 | -51.5 | -63.2 | -28.2 |
| ROE (net income / shareholders' equity) | -27.8% | -39.4% | -66.8% | -73.6% | -152% | -114% |
| ROA (Net income/ Total Assets) | -15% | -21.4% | -37.3% | -38.8% | -75% | -56.3% |
| Assets 1 | 185.4 | 255.7 | 241.1 | 232.3 | 153.4 | 70.44 |
| Book Value Per Share 2 | 84.10 | 65.30 | 44.80 | 29.00 | 2.170 | -0.4000 |
| Cash Flow per Share 2 | 27.10 | 26.30 | 19.00 | 30.30 | 15.40 | 5.230 |
| Capex 1 | 1.23 | 0.21 | 0.01 | 0.06 | 0.15 | 0.13 |
| Capex / Sales | 4.74% | 0.96% | - | - | 1.51% | - |
| Announcement Date | 3/8/18 | 3/7/19 | 3/11/20 | 3/16/21 | 3/31/22 | 3/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 97.45K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CALA Stock
- Financials Calithera Biosciences, Inc.
